Pouneh K. Fazeli, MD
Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.
Anorexia nervosa is a prevalent psychiatric with a lifetime prevalence of up to 2.2%. Among the many medical co-morbidities associated with anorexia nervosa, the most common is significant bone loss, which can persist despite weight recovery. Nearly 90% of women with anorexia nervosa have osteopenia and this low bone mass is associated with an increased fracture risk. Nearly 30% of women with anorexia nervosa report a history of a fracture and a prospective study demonstrated a 7-fold increased risk of fracture in women with anorexia nervosa compared to age-matched controls. Because anorexia n…
Inclusion Criteria: 1. Female 2. 19-45 years of age 3. DSM-5 psychiatric criteria for anorexia nervosa 4. \<85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height and Weight Tables 5. Amenorrhea 6. T-score of \< -1.0 at spine or hip Exclusion Criteria: 1. Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency (eGFR \< 60) 2. Personal history of venous or arterial clot 3. History of stroke or myocardial infarction 4. History of hypercoagulable disorder 5.…
Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
Placebo weekly patch
Arctuva estimate
Verify or correct the compensation shown for this listing.